Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Celldex Therapeutics (CLDX) Other Non-Current Assets (2016 - 2025)

Celldex Therapeutics (CLDX) has 16 years of Other Non-Current Assets data on record, last reported at $9.4 million in Q3 2025.

  • For Q3 2025, Other Non-Current Assets fell 3.93% year-over-year to $9.4 million; the TTM value through Sep 2025 reached $9.4 million, down 3.93%, while the annual FY2024 figure was $9.7 million, 9009.35% up from the prior year.
  • Other Non-Current Assets reached $9.4 million in Q3 2025 per CLDX's latest filing, down from $9.7 million in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $9.7 million in Q3 2024 and bottomed at $41000.0 in Q1 2021.
  • Average Other Non-Current Assets over 5 years is $1.8 million, with a median of $104000.0 recorded in 2021.
  • Peak YoY movement for Other Non-Current Assets: soared 9009.35% in 2024, then decreased 3.93% in 2025.
  • A 5-year view of Other Non-Current Assets shows it stood at $104000.0 in 2021, then changed by 0.0% to $104000.0 in 2022, then rose by 2.88% to $107000.0 in 2023, then skyrocketed by 9009.35% to $9.7 million in 2024, then decreased by 3.93% to $9.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other Non-Current Assets were $9.4 million in Q3 2025, $9.7 million in Q4 2024, and $9.7 million in Q3 2024.